Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Show more

170 Harbor Way, South San Francisco, CA, 94080, United States

Biotechnology
Healthcare

Market Cap

147.3M

52 Wk Range

$0.26 - $0.84

Previous Close

$0.60

Open

$0.59

Volume

254,790

Day Range

$0.59 - $0.64

Enterprise Value

69.96M

Cash

63.81M

Avg Qtr Burn

N/A

Insider Ownership

1.57%

Institutional Own.

0.05%

Qtr Updated

12/31/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2b

Data readout

Phase 2b

Update

Phase 2

Update

Phase 2

Update

Phase 1

Data readout

Phase 1

Update